Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD 0332991 (Palbociclib) in Refractory Solid Tumors
NCT01037790Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Oct 2009
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in breast cancer, colorectal cancer (CRC), esophageal cancer, gastric cancer (GC), germ cell tumor (GCT), sponsored by Abramson Cancer Center. Started Oct 2009; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancercolorectal cancer (CRC)esophageal cancergastric cancer (GC)germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT01037790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01037790.